Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19115649 | 0.84 | MAP2K4 (0.36) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL27051467 | 0.80 | — | — | |
| SCHEMBL19104231 | 0.80 | MAPK1 (0.32) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL12593579 | 0.78 | MAPK1 (0.49) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL18408664 | 0.76 | CYP1A2 (0.37) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL25667783 | 0.74 | MAPK1 (0.37) | MAPK1 | |
| SCHEMBL23206119 | 0.73 | GAA (0.35) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL16646966 | 0.73 | MAPK1 (0.33) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL25667658 | 0.73 | MAPK1 (0.40) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL25667774 | 0.73 | MAPK1 (0.33) | MAPK1MAP2K4MAPKAPK2MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | MAPK1 146/4885MAP2K4 340/4885MAPKAPK2 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.